LINC01476: LINC01476 is a long non-coding RNA (lncRNA) that has been found to have lower expression in glioblastomas (GBMs) compared to normal brain tissue [PMC5140055]. In a study using tissue samples from patients at the University of Virginia, the altered expression of LINC01476 was validated [PMC5140055]. LINC01476 is involved in a structural variation (SV) that disrupts the genomic region spanning YPEL2 to LINC01476 [PMC7675008]. This SV also involves other genes, including GDPD1, MIR4729, SMG8, PRR11, and YPEL2 [PMC7675008]. The RP17 SVs share a common duplicated region and have breakpoints in LINC01476 intron 2 and YPEL2 intron 4 [PMC7675008]. The RP17 SVs lead to the disruption of the genomic region spanning YPEL2 to LINC01476 [PMC7675008]. Furthermore, methylation levels in specific sites of LINC01476 have been observed to decrease with increased severity score [PMC9235511]. The top 10 CpG sites mapped to various genes including LEP, CDHR4, MAD1L1, CLK3, ESD, HPCAL1, PTH and three long non-coding RNAs with unknown function in bone metabolism (LINC00301 and LINC01699) [PMC9235511]. In summary, LINC01476 is a lncRNA that has lower expression in GBMs compared to normal brain tissue. It is involved in a structural variation that disrupts the genomic region spanning YPEL2 to LINC01476. Methylation levels of specific sites within LINC01476 have been observed to decrease with increased severity score.